Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have received a consensus rating of “Hold” from the nine research firms that are covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and five have issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $14.00.

A number of equities research analysts have weighed in on BCYC shares. Citizens Jmp lowered their price objective on Bicycle Therapeutics from $12.00 to $8.00 and set a “market outperform” rating for the company in a research note on Wednesday, March 18th. Wall Street Zen lowered Bicycle Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, May 10th. Weiss Ratings restated a “sell (e+)” rating on shares of Bicycle Therapeutics in a research note on Friday, April 10th. Jefferies Financial Group restated a “buy” rating and set a $12.00 price objective on shares of Bicycle Therapeutics in a research note on Thursday, April 30th. Finally, Needham & Company LLC lowered their price objective on Bicycle Therapeutics from $24.00 to $15.00 and set a “buy” rating for the company in a research note on Wednesday, March 18th.

Insider Buying and Selling

In other Bicycle Therapeutics news, CEO Kevin Lee sold 5,967 shares of the stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $4.91, for a total transaction of $29,297.97. Following the transaction, the chief executive officer owned 613,029 shares of the company’s stock, valued at $3,009,972.39. This trade represents a 0.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 9,992 shares of company stock worth $49,363. Company insiders own 22.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of BCYC. GSK plc bought a new position in Bicycle Therapeutics during the 4th quarter worth approximately $10,829,000. Schroder Investment Management Group bought a new position in Bicycle Therapeutics during the 4th quarter worth approximately $3,976,000. Principal Financial Group Inc. lifted its holdings in Bicycle Therapeutics by 64.7% during the 3rd quarter. Principal Financial Group Inc. now owns 1,148,402 shares of the company’s stock worth $8,889,000 after buying an additional 451,135 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in Bicycle Therapeutics by 72.8% during the 1st quarter. Renaissance Technologies LLC now owns 979,300 shares of the company’s stock worth $4,544,000 after buying an additional 412,700 shares during the last quarter. Finally, Woodline Partners LP bought a new position in Bicycle Therapeutics during the 1st quarter worth approximately $3,088,000. Institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Price Performance

Shares of NASDAQ BCYC opened at $4.55 on Monday. Bicycle Therapeutics has a fifty-two week low of $4.24 and a fifty-two week high of $9.36. The business has a 50 day moving average price of $4.79 and a two-hundred day moving average price of $5.85. The firm has a market cap of $317.18 million, a PE ratio of -1.44 and a beta of 1.56.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.25). Bicycle Therapeutics had a negative net margin of 344.95% and a negative return on equity of 35.74%. The business had revenue of $0.89 million for the quarter, compared to analyst estimates of $7.50 million. On average, analysts anticipate that Bicycle Therapeutics will post -1.98 earnings per share for the current year.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.